An Open-Labeled Study to Evaluate Efficacy of Combining Cetuximab Plus Concurrent Chemo-Radiotherapy in Loco-Regional Esophageal Squamous Cell Carcinoma (ESCC).
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms EXCEL
- 08 Feb 2011 Biomarkers information updated
- 04 Feb 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 04 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.